Posts by: Patricia Inacio, PhD

Patricia Inacio, PhD

Patricia holds her Ph.D. in Cell Biology from University Nova de Lisboa, and has served as an author on several research projects and fellowships, as well as major grant applications for European Agencies. She also served as a PhD student research assistant in the Laboratory of Doctor David A. Fidock, Department of Microbiology & Immunology, Columbia University, New York.

July 18, 2018

Ninlaro Maintenance Therapy Fares Well in Phase 3 Multiple Myeloma Trial

News

Takeda‘s proteasome inhibitor Ninlaro (ixazomib) prevents multiple myeloma from progressing or returning when given as a maintenance therapy to patients who responded to first-line therapy and stem cell transplant, a Phase ... Read more

June 29, 2018

Empliciti Triple Combo Delays Disease Progression in Advanced Myeloma Patients, Phase 2 Trial Data Show

News

Adding Empliciti (elotuzumab) to a combination of Pomalyst (pomalidomide) and dexamethasone significantly delays disease worsening or death in myeloma patients who failed to respond to previous treatment, data from the Phase 2 ELOQUENT-3 trial ... Read more

June 25, 2018

Mutations in Noncoding Regions of Human Genome Also Cause Cancer, Study Shows

News

While the best described cancer mutations are in regions that provide instructions to make proteins, most mutations actually happen in the noncoding regions of our genome, researchers found. University ... Read more

June 22, 2018

Advanced Myeloma Patients Responding to Selinexor Plus Standard Therapies in Trial, Data Show

News

Updated clinical trial data show that selinexor added to standard therapies can benefit multiple myeloma patients who have failed multiple prior lines of therapy, Karyopharm Therapeutics announced. This data — from the ... Read more

May 14, 2018

FDA Names Cancer Vaccine Galinpepimut-S Orphan Drug as Possible Multiple Myeloma Treatment

News

The investigational cancer vaccine galinpepimut-S (GPS) has been designated an orphan drug by the U.S. Food and Drug Administration as a possible treatment of multiple myeloma, Sellas Life Sciences ... Read more

March 21, 2018March 21, 2018

Medicinal Cannabis Safe and Effective for Pain, Chemo Side Effects, Journal Says

News

The supervised use of medicinal cannabis is safe and effective at relieving pain and reducing chemotherapy-induced nausea and vomiting in cancer patients, an increasing body of research data shows. In ... Read more

March 16, 2018

Trial to Explore Benefits of Exercise Before Autologous Stem Cell Transplant in Myeloma Patients

News

A new clinical trial will determine if an exercise program before an autologous stem cell transplant can improve treatment-related side effects in multiple myeloma patients. The trial details are summarized ... Read more

March 14, 2018March 14, 2018

Seattle Genetics Starts Phase 1 Trial Testing SGN-CD48A in Relapsed or Refractory Myeloma

News

Seattle Genetics‘ investigational therapy SGN-CD48A, being evaluated in a Phase 1 clinical trial for relapsed or refractory multiple myeloma, was successfully delivered to the trial’s first patient, the company ... Read more

March 12, 2018March 12, 2018

Patients with MGUS Have a Low But Persistent Risk of Multiple Myeloma, Study Finds

News

Patients with a condition called monoclonal gammopathy of undetermined significance, characterized by the presence of the abnormal monoclonal or M protein, have a small but persistent risk of multiple myeloma or ... Read more

January 24, 2018

FDA to Give Priority Review to Darzalex Combinations for Multiple Myeloma

News

The U.S. Food and Drug Admnistration will give priority review to Darzalex (daratumumab) as an add-on to standard treatments for multiple myeloma patients who cannot have a stem cell transplant. ... Read more